Clesrovimab - Merck Sharp & Dohme
Alternative Names: Anti RSV F antibody - Merck Sharp & Dohme; clesrovimab-cfor - Merck Sharp & Dohme; ENFLONSIA; Enflonsia; MK-1654Latest Information Update: 23 Feb 2026
At a glance
- Originator Merck Sharp & Dohme
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Respiratory syncytial virus infections
Most Recent Events
- 19 Feb 2026 Updated efficacy, pharmacokinetics and adverse events data from the phase III SMART trial in Respiratory syncytial virus infections released by Merck Sharp & Dohme
- 05 Feb 2026 Registered for Respiratory syncytial virus infections (In neonates, In infants, Prevention) in Canada (IM)
- 05 Feb 2026 Adverse events data from a phase IIb/III CLEVER trial in Respiratory syncytial virus infections released by Merck